Longer RFS with Nivolumab Than with Ipilimumab Among Patients with Resected Stage IIIB-C or Stage IV Melanoma By Ogkologos - February 2, 2026 289 0 Facebook Twitter Google+ Pinterest WhatsApp Final data from the CheckMate 238 study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Strengthens Global Oncology Collaboration Through its Growing Presence in the Asia-Pacific Pemigatinib Prolongs mPFS Over Chemotherapy in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements FDA Approves Atezolizumab for Adjuvant Treatment of Muscle Invasive Bladder Cancer in Patients with Molecular Residual Disease MOST POPULAR Whole-Genome Sequencing Could Help Guide AML Treatment April 6, 2021 Greater Severity of Adverse Events in Women Across Multiple Anticancer Treatment... February 11, 2022 FDA Grants Accelerated Approval to Zongertinib for Unresectable or Metastatic Non-Squamous... March 18, 2026 FDA Approves Polatuzumab Vedotin-piiq for Previously Untreated Diffuse Large B-Cell Lymphoma,... April 27, 2023 Load more HOT NEWS Ranking of Molecular Alterations in HNSCC According to ESCAT Classification Provides... Twins Born 15 Minutes Apart Have Birthdays In Different Years The Recently Leaked Secret to Marijuana News Discovered Three cancer drugs approved for NHS use in Scotland
